Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZX-29 是一种选择性ALK 抑制剂,对ALK、ALK L1196M 和ALK G1202R 的IC50分别为 2.1 nM、1.3 nM 和 3.9 nM。它还可诱导保护性自噬并具有抗肿瘤作用。它通过诱导内质网应激来诱导细胞凋亡,并克服了由ALK 突变引起的细胞抗性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 996 | 现货 | ||
5 mg | ¥ 2,420 | 现货 | ||
10 mg | ¥ 3,890 | 现货 | ||
25 mg | ¥ 6,250 | 现货 | ||
50 mg | ¥ 8,580 | 现货 | ||
100 mg | ¥ 11,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,190 | 现货 |
产品描述 | ZX-29 is a potent and selective inhibitor of ALK(IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively), and also induces protective autophagy and has antitumor effect. |
靶点活性 | ALK:2.1 nM , ALK (F1196M):1.3 nM , ALK (G1202R):3.9 nM |
体外活性 | ZX-29 dose-dependently inhibits colony formation of NCI-H2228 cells. With an increase in ZX-29 concentration, the cell density decreased gradually, and the cells lost their normal morphology and become sharp and slender. In NCI-H2228 cells, ZX-29 (10 nM; 0-48 hours) inhibits the proliferation of and arrests the cells in G1 phase. ZX-29 (0-81 nM; 24-72 hours) treatment resulted in a decrease in the viability with time and dose. ZX-29 (10 nM; 24 hours) treatment causes typical signs of autophagy and the formation of autophagosomes and enhances the expression level of LC3 and Beclin1. ZX-29 (20 nM; 0-48 hours) treatment significantly increases the mRNA level of CHOP[1]. |
体内活性 | In a mouse xenograft model, ZX-29 treatment suppresses tumor growth[1]. |
分子量 | 518.03 |
分子式 | C23H28ClN7O3S |
CAS No. | 2254805-62-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 42.5 mg/mL (82.04 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9304 mL | 9.652 mL | 19.3039 mL | 48.2598 mL |
5 mM | 0.3861 mL | 1.9304 mL | 3.8608 mL | 9.652 mL | |
10 mM | 0.193 mL | 0.9652 mL | 1.9304 mL | 4.826 mL | |
20 mM | 0.0965 mL | 0.4826 mL | 0.9652 mL | 2.413 mL | |
50 mM | 0.0386 mL | 0.193 mL | 0.3861 mL | 0.9652 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ZX-29 2254805-62-2 Angiogenesis Tyrosine Kinase/Adaptors ALK arrest antitumor ZX29 Resistance Anaplastic lymphoma kinase Bcl-2 Apoptosis Inhibitor CD246 p-Akt caspase-3 endoplasmic inhibit CHOP Anaplastic lymphoma kinase (ALK) ALK tyrosine kinase receptor ERS Cluster of differentiation 246 Autophagy reticulum p-STAT3 ZX 29 inhibitor